ADIAL PHARMACEUTICALS, INC. Files 2023 Annual Report on Form 10-K

TL;DR

<b>ADIAL PHARMACEUTICALS, INC. has filed its 2023 annual report on Form 10-K, detailing its financial performance and operations.</b>

AI Summary

ADIAL PHARMACEUTICALS, INC. (ADIL) filed a Annual Report (10-K) with the SEC on April 1, 2024. ADIAL PHARMACEUTICALS, INC. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is registered with the SEC under the Central Index Key 0001513525. Its common stock trades under the symbol ADIL on The Nasdaq Stock Market LLC. ADIAL PHARMACEUTICALS, INC. is incorporated in Delaware and its fiscal year ends on December 31. The company is classified as a non-accelerated filer and a smaller reporting company.

Why It Matters

For investors and stakeholders tracking ADIAL PHARMACEUTICALS, INC., this filing contains several important signals. This filing provides a comprehensive overview of ADIAL PHARMACEUTICALS, INC.'s financial health, operational status, and strategic outlook for the fiscal year 2023. Investors and stakeholders can use this report to assess the company's performance, risks, and future prospects, particularly concerning its common stock traded under ADIL.

Risk Assessment

Risk Level: low — ADIAL PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant negative news, indicating a routine disclosure.

Analyst Insight

Review the full 10-K filing for detailed financial statements, risk factors, and management's discussion and analysis to understand ADIAL PHARMACEUTICALS, INC.'s current business standing.

Key Numbers

• 2023 — Fiscal Year End (Fiscal year ended December 31, 2023)
• 10-K — Form Type (Form type filed)
• 001-38323 — Commission File Number (SEC Commission file number)
• ADIL — Trading Symbol (Common Stock Trading Symbol)

Key Players & Entities

• ADIAL PHARMACEUTICALS, INC. (company) — Filer name
• ADIL (company) — Trading symbol
• The Nasdaq Stock Market LLC (company) — Exchange where common stock is registered
• 0001213900-24-028701 (dollar_amount) — Accession number
• 20231231 (dollar_amount) — Conformed period of report
• 20240401 (dollar_amount) — Filed as of date
• 0001513525 (dollar_amount) — Central Index Key
• DE (company) — State of incorporation

FAQ

Industry Context

Adial Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing treatments.

Regulatory Implications

The company is subject to standard SEC reporting requirements for publicly traded companies, including the annual filing of Form 10-K.

What Investors Should Do

1. Thoroughly review the 'Business', 'Risk Factors', and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of the 10-K.
2. Analyze the company's financial statements (balance sheets, income statements, cash flow statements) for the fiscal year ended December 31, 2023.
3. Compare key financial metrics and disclosures with previous filings to identify trends and changes.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-04-01: Filing Date — Date the 10-K report was filed with the SEC.

Year-Over-Year Comparison

This is the annual 10-K filing for the fiscal year ended December 31, 2023, providing updated information since the previous reporting period.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share ADIL The Nasdaq Stock Market
• $450,000 — ve May 16, 2023 and made payment of the $450,000 in fees due on exercise. Effective June
• $2.82 — 's Common Stock at an exercise price of $2.82 per share, and (iii) series B warrants
• $0.125 — t, upon the payment by the Purchaser of $0.125 per share in addition to the exercise p
• $2.819 — rrant and the accompanying Warrants was $2.819. The net proceeds to us from the Privat
• $3.4 m — he Private Placement were approximately $3.4 million, after deducting placement agent
• $1,418 — ad been exercised for total proceeds of $1,418. Warrant Exercise On March 1, 2024,
• $757 thousand — sed for gross proceeds of approximately $757 thousand. Warrant Exercise Inducement Agreement
• $3.5 m — gregate gross proceeds of approximately $3.5 million, before deducting placement agent
• $3.1 million — tion were estimated to be approximately $3.1 million. In consideration of the Holder's imme

Filing Documents

• ea0202434-10k_adial.htm (10-K) — 1464KB
• ea020243401ex21-1_adialph.htm (EX-21.1) — 1KB
• ea020243401ex23-1_adialph.htm (EX-23.1) — 2KB
• ea020243401ex31-1_adialph.htm (EX-31.1) — 11KB
• ea020243401ex31-2_adialph.htm (EX-31.2) — 12KB
• ea020243401ex32-1_adialph.htm (EX-32.1) — 4KB
• ea020243401ex32-2_adialph.htm (EX-32.2) — 4KB
• ea020243401ex97-1_adialph.htm (EX-97.1) — 26KB
• 0001213900-24-028701.txt (&nbsp;) — 6272KB
• adil-20231231.xsd (EX-101.SCH) — 57KB
• adil-20231231_cal.xml (EX-101.CAL) — 43KB
• adil-20231231_def.xml (EX-101.DEF) — 292KB
• adil-20231231_lab.xml (EX-101.LAB) — 542KB
• adil-20231231_pre.xml (EX-101.PRE) — 290KB
• ea0202434-10k_adial_htm.xml (XML) — 485KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 24 Item 1B. Unresolved Staff Comments 59 Item 1C. Cybersecurity 59 Item 2.

Properties

Properties 60 Item 3.

Legal Proceedings

Legal Proceedings 60 Item 4. Mine Safety Disclosures 60 PART II Item 5. Market for Registrant's Common Equity Related Stockholder Matters and Issuer Purchases of Equity Securities 61 Item 6. [Reserved] 63 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 63 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 72 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 73 Item 9A.

Controls and Procedures

Controls and Procedures 73 Item 9B. Other Information 74 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 74 PART III Item 10. Directors, Executive Officers and Corporate Governance 75 Item 11.

Executive Compensation

Executive Compensation 81 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 88 Item 13. Certain Relationships and Related Transactions, and Director Independence 90 Item 14. Principal Accountant Fees and Services 93 PART IV Item 15. Exhibit and Financial Statement Schedules 94 Item 16. Form 10-K Summary 94

SIGNATURES

SIGNATURES 99 i PART I ADIAL PHARMACEUTICALS, INC. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains "forward-looking Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In particular, statements contained in this Annual Report on Form 10-K, including but not limited to, statements regarding the sufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities; our future results of operations and financial position, business strategy and plan prospects, or costs and objectives of management for future initiatives, are forward-looking statements. These forward-looking statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as "may," "will," "should," "expects," "plans," "anticipates," "intends," "targets," "projects," "contemplates," "believes," "seeks," "goals," "estimates," "predicts," "potential" and "continue" or similar words. Readers are cautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified below, under Part I, Item lA. "Risk Factors" and elsewhere in this Annual Report on Form 10-K. Therefore, actual results may differ materially and adversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward-looking statements for any reason. NOTE REGARDING COMPANY REFERENCES Throughout this Annual Report on Form 10-K, "Adial," the "Company," "we," "us" and "our" refer to Adial Pharmaceuticals, Inc. Summary Risk Factors Our business faces significant risks and uncertainties of which investors shoul

Business

Item 1. Business. Overview We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder ("AUD"). AD04 was recently investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis of the subgroup data from the ONWARD trial, we are now focused on completing the clinical development program for AD04 in the specified genetic subgroups to meet regulatory requirements primarily in the U.S. and secondarily in Europe/UK. In January 2021, we expanded our portfolio in the field of addiction with the acquisition of Purnovate, LLC via a merger into our wholly owned subsidiary, Purnovate, Inc. ("Purnovate") and in January 2023, we entered into an option agreement with Adovate LLC ("Adovate"), pursuant to which we granted to Adovate an exclusive option for Adovate or its designated affiliate to acquire all of the assets of Purnovate and to assume related liabilities and expenses. (Our then-CEO was a significant equity holder in Adovate, LLC, so this was considered a related party transaction.) On May 8, 2023, Adovate sent a letter exercising its option effective May 16, 2023 and made payment of the $450,000 in fees due on exercise. Effective June 30, 2023, Adovate issued to us the equity stake in Adovate due on exercise of the option agreement. On August 17, 2023, a Bill of Sale, Assignment and Assumption Agreement ("Bill of Sale") was executed between Purnovate and Adovate, transferring the Purnovate assets to Adovate, effective as of June 30, 2023. On August 17, 2023, Purnovate and Adovate also entered into a letter agreement acknowledging that Adovate acquired the assets of P

View Full Filing

View this 10-K filing on SEC EDGAR